Small-Molecule Ligands for Myotonic Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for myotonic dystrophy are not highly selective, are toxic, or less effective in inhibiting MBNL1-RNA interactions, which are central to the disease's pathology.
Innovation Solution
Development of a new series of small-molecule ligands that selectively inhibit MBNL1-RNA interactions with high efficacy and low toxicity, designed to restore proper splicing of misspliced mRNAs by binding to CUG or CTG repeats, thereby addressing the root cause of myotonic dystrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to inhibit MBNL1-RNA interactions, then some therapeutic effect is achieved, but the agents lack high selectivity and exhibit toxicity
Solution Approach 1:
The patent applies local quality by designing small molecules with specific structural features (amidine or guanidine groups flanked by aromatic rings) that locally target the unique structure of CUG/CTG repeat RNA. This localized molecular design enables high selectivity for the pathological RNA substrate while avoiding off-target effects that cause toxicity in current agents
Solution Approach 2:
The patent employs parameter changes by optimizing molecular parameters such as the pKa of amidine/guanidine groups (to ensure proper ionization state for RNA binding), the spacing and orientation of aromatic rings, and the overall molecular size. These parameter optimizations enable the compounds to achieve high binding affinity and selectivity for CUG/CTG repeats while maintaining low toxicity profiles
2Reliability
If current therapeutic agents are used, then some inhibition of MBNL1-RNA interactions is achieved, but the efficacy is insufficient
Solution Approach 1:
The patent applies composite materials by combining multiple functional elements within each small molecule: aromatic rings for pi-stacking interactions with CUG/CTG repeats, amidine or guanidine groups for electrostatic and hydrogen bonding interactions, and carefully designed linkers for optimal spatial arrangement. This composite molecular structure achieves superior efficacy compared to current single-function agents
3Reliability
If a drug binds to CUG repeats to free MBNL protein, then splicing regulation is restored, but the binding must be highly selective to avoid off-target effects
Solution Approach 1:
The patent uses small molecules as intermediaries that bind to CUG/CTG repeat RNA and displace MBNL1 protein without directly interacting with the protein itself. This intermediary approach restores MBNL1-mediated splicing regulation by freeing the protein from pathological RNA sequestration while the small molecule's selective structure prevents off-target binding to non-CUG/CTG RNA sequences
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small-molecule ligands effectively inhibit MBNL1-RNA interactions, restore proteins associated with misspliced mRNAs, and demonstrate non-toxicity in cell cultures, offering a promising therapeutic strategy for myotonic dystrophy with potential for clinical application.
Implementation Method 1
A drug that binds to CUG repeats, thereby freeing MBNL to regulate splicing of its pre-mRNA targets
Data Source
AI summary
The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.